This is a good development. Who's going to have access to this medication if it comes to market? Will it be for the wealthy or will the poor have access to it?

Some of it depends on the cost of manufacture. If it’s tailored to each individual and scaling it is difficult but the drug is effective then it’d likely be costly. If scalability is easy then it’ll be relatively affordable.

As with almost everything: first one, then the other.